Drugs / AD-203
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | Other | — | — | 2020-12-01 | “애드파마가 개발하고 있는 AD-203이 임상시험을 완료하고 식약처에 허가신청했다.” addpharma.co.kr ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04066530 | Sep 2019 → Feb 2020 | chronic gastritis | Addpharma Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-12-01 | Addpharma Inc. | Regulatory 레바미피드 서방정, 허가 신청·상업화 임박 addpharma.co.kr ↗
7일 업계에 따르면 유한양행의 자회사인 애드파마가 개발하고 있는 AD-203이 임상시험을 완료하고 식약처에 허가신청했다. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-12-01 | Addpharma Inc. | 레바미피드 서방정, 허가 신청·상업화 임박 addpharma.co.kr ↗ |
| 2019-08-01 | Addpharma Inc. | 위염 치료제 AD-203, 임상 3상 승인 addpharma.co.kr ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04066530 ↗ |